Introduction

The changing BN prescribing dynamics in the 4th quarter of 2016, particularly with the widespread availability of Suboxone® (Bunavail®), a prescription service, the number of patients in a large state in the US. The conversion dataset comprised 1,373 unique providers ordering approximately 643,225 prescriptions for opiod substitution therapy, which had been expected to encourage 37% of all prescriptions within the drug class. The urine toxicology dataset, derived from six national toxicology laboratories, was supplied by(s) the number of addiction medicine physicians in the state Medicaid plan, SLBN, and BN prior to and after conversion to BBN.

Methods

Prescription Claims and Taxonomy Analysis

For the period January 1, 2015 through December 31, 2016, we examined tax classes comprised, respectively, of addiction treatment prescription writings and taxonomic test results for patients in a large state in the US. The conversion dataset comprised 1,373 unique providers ordering approximately 643,225 prescriptions for opioid substitution therapy, which had been expected to encourage 37% of all prescriptions written in the drug class. The urine toxicology dataset, derived from six national toxicology laboratories, was supplied by(s) the number of addiction medicine physicians in the state Medicaid plan, SLBN, and BN prior to and after conversion to BBN.

Methods (cont.)

Prescription Claims and Assessment of Costs

A few-side-state Medicaid plan modified their BN formulary to make BBN (Bunavail®) a preferred BN formulation (Bunavail®, Indivior, Inc., Richmond, VA, USA). Buprenorphine use has been shown to deliver biodemographic benefits to patients in terms of ease of misuse/diversion and illicit distribution of BN. Reduced Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion

Results

To utilize prescription claims data, toxicology results, and longitudinal data, this study was designed to capture feedback about physician experiences with the BN market, SLBN, and BBN prior to and after conversion to BBN.

Results (cont.)

• Among patients prescribed opioid analgesics, approximately 10% develop opioid addiction. Such patients may derive benefit from medication-assisted treatment with a longacting, buprenorphine-containing (BBN).
• With increased availability and utilization of BN formulations, concerns have been raised about potential misuse and diversion of these products.
• For example, among opioid abusers presenting for substance abuse treatment, 32.1% reported prior intranasal misuse of BN.

Objective

To utilize prescription claims data, toxicology results, and physician survey data on the impact of the conversion from SLBN to BBN on their opioid treatment patients.

Methods

Prescription Claims and Assessment of Costs

A few-side-state Medicaid plan modified their BN formulary to make BBN (Bunavail®) a preferred BN formulation (Bunavail®, Indivior, Inc., Richmond, VA, USA). Buprenorphine use has been shown to deliver biodemographic benefits to patients in terms of ease of misuse/diversion and illicit distribution of BN.

Figures

Figure 1. Monthly prescription counts for SLBN prior to and after the formulary conversion to BBN

Figure 2. Monthly prescription counts for the overall BN market, SLBN, and BBN prior to and after conversion

Figure 3. State Medicaid plan taxiology findings related to misuse and costs.

Figure 4. Survey questions related to ease of misuse/abuse

Discussion

The overall experience was reported to be with patients’ families, we are confident that the conversion of patients was a positive (very positive [15%], somewhat positive [37%]) outcome, 64% of all BN patients opted to switch from SLBN to BBN compared with SLBN in terms of the ease with which they can be misused or diverted. The overall experience was reported to be with patients’ families, we are confident that the conversion of patients was a positive (very positive [15%], somewhat positive [37%]) outcome, 64% of all BN patients opted to switch from SLBN to BBN compared with SLBN in terms of the ease with which they can be misused or diverted.

Physician Survey

Among 77,067 unique patients tested during calendar 2015, drug related to opioids and cocaine.

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

SLBN. In those that discontinued BBN therapy, 64% opted to try BBN and 77% were still taking BBN at the end of the 3-month period.

The urine toxicology dataset, derived from six national toxicology laboratories, was supplied by(s) the number of addiction medicine physicians in the state Medicaid plan, SLBN, and BN prior to and after conversion to BBN.

Patient and order volumes and the rate of positive urine laboratory results from a broad range of states revealed an approximate 1,500 prescriptions per month in the last two quarters of 2015. The urine toxicology dataset, derived from six national toxicology laboratories, was supplied by(s) the number of addiction medicine physicians in the state Medicaid plan, SLBN, and BN prior to and after conversion to BBN.

1;142:98-104.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

• Reduced Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone® to Bunavail®: Implications for Potential Diversion

Richard Soper, MD, JD, MS1, Michael Bullock2, Christina DEXIMO9, Paul Blake, FCPG

1Center for Behavioral Wellness, Nashville, TN; 2BioDelivery Sciences International, Inc., Raleigh, NC, USA. 3hc1 Insight LLC, a wholly-owned subsidiary of hc1.com Inc., Indianapolis, IN.

Discussion

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

To utilize prescription claims data, toxicology results, and physician survey data on the impact of the conversion from SLBN to BBN on their opioid treatment patients.

Methods

Prescription Claims and Assessment of Costs

A few-side-state Medicaid plan modified their BN formulary to make BBN (Bunavail®) a preferred BN formulation (Bunavail®, Indivior, Inc., Richmond, VA, USA). Buprenorphine use has been shown to deliver biodemographic benefits to patients in terms of ease of misuse/diversion and illicit distribution of BN. Reduced Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion

Results

To utilize prescription claims data, toxicology results, and physician survey data on the impact of the conversion from SLBN to BBN on their opioid treatment patients.

Methods

Prescription Claims and Assessment of Costs

A few-side-state Medicaid plan modified their BN formulary to make BBN (Bunavail®) a preferred BN formulation (Bunavail®, Indivior, Inc., Richmond, VA, USA). Buprenorphine use has been shown to deliver biodemographic benefits to patients in terms of ease of misuse/diversion and illicit distribution of BN.

Results

To utilize prescription claims data, toxicology results, and physician survey data on the impact of the conversion from SLBN to BBN on their opioid treatment patients.

Methods

Prescription Claims and Assessment of Costs

A few-side-state Medicaid plan modified their BN formulary to make BBN (Bunavail®) a preferred BN formulation (Bunavail®, Indivior, Inc., Richmond, VA, USA). Buprenorphine use has been shown to deliver biodemographic benefits to patients in terms of ease of misuse/diversion and illicit distribution of BN. Reduced Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion

Physician Survey

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.

Physician Survey Questions

The rapid reduction in the overall BN market following a complete formulary switch from SLBN to BBN resulted in a quarterly cost savings of $3.5 million for the state Medicaid program.